nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—Chest pain—Docetaxel—lung cancer	0.000333	0.000376	CcSEcCtD
Anagrelide—Myalgia—Docetaxel—lung cancer	0.000333	0.000376	CcSEcCtD
Anagrelide—Arthralgia—Docetaxel—lung cancer	0.000333	0.000376	CcSEcCtD
Anagrelide—Pancytopenia—Doxorubicin—lung cancer	0.000333	0.000376	CcSEcCtD
Anagrelide—Nausea—Vinorelbine—lung cancer	0.000333	0.000375	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Etoposide—lung cancer	0.000332	0.000374	CcSEcCtD
Anagrelide—Dyspepsia—Paclitaxel—lung cancer	0.000332	0.000374	CcSEcCtD
Anagrelide—Body temperature increased—Cisplatin—lung cancer	0.000332	0.000374	CcSEcCtD
Anagrelide—Asthenia—Irinotecan—lung cancer	0.000332	0.000374	CcSEcCtD
Anagrelide—Fatigue—Etoposide—lung cancer	0.000331	0.000374	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000331	0.000373	CcSEcCtD
Anagrelide—Pain—Etoposide—lung cancer	0.000329	0.000371	CcSEcCtD
Anagrelide—Constipation—Etoposide—lung cancer	0.000329	0.000371	CcSEcCtD
Anagrelide—Dysuria—Doxorubicin—lung cancer	0.000328	0.00037	CcSEcCtD
Anagrelide—Decreased appetite—Paclitaxel—lung cancer	0.000328	0.00037	CcSEcCtD
Anagrelide—Dry mouth—Docetaxel—lung cancer	0.000326	0.000368	CcSEcCtD
Anagrelide—Haemoglobin—Methotrexate—lung cancer	0.000326	0.000367	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000325	0.000367	CcSEcCtD
Anagrelide—Fatigue—Paclitaxel—lung cancer	0.000325	0.000366	CcSEcCtD
Anagrelide—Hepatitis—Methotrexate—lung cancer	0.000324	0.000366	CcSEcCtD
Anagrelide—Haemorrhage—Methotrexate—lung cancer	0.000324	0.000366	CcSEcCtD
Anagrelide—Pollakiuria—Doxorubicin—lung cancer	0.000324	0.000365	CcSEcCtD
Anagrelide—Asthenia—Gemcitabine—lung cancer	0.000323	0.000364	CcSEcCtD
Anagrelide—Pain—Paclitaxel—lung cancer	0.000322	0.000363	CcSEcCtD
Anagrelide—Constipation—Paclitaxel—lung cancer	0.000322	0.000363	CcSEcCtD
Anagrelide—Confusional state—Docetaxel—lung cancer	0.000322	0.000363	CcSEcCtD
Anagrelide—Pharyngitis—Methotrexate—lung cancer	0.000322	0.000363	CcSEcCtD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	0.000321	0.00284	CbGpPWpGaD
Anagrelide—Urinary tract disorder—Methotrexate—lung cancer	0.00032	0.000361	CcSEcCtD
Anagrelide—Photosensitivity reaction—Doxorubicin—lung cancer	0.00032	0.000361	CcSEcCtD
Anagrelide—Oedema—Docetaxel—lung cancer	0.000319	0.00036	CcSEcCtD
Anagrelide—Weight increased—Doxorubicin—lung cancer	0.000319	0.00036	CcSEcCtD
Anagrelide—Pruritus—Gemcitabine—lung cancer	0.000318	0.000359	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—GSTA4—lung cancer	0.000318	0.00281	CbGpPWpGaD
Anagrelide—Urethral disorder—Methotrexate—lung cancer	0.000318	0.000358	CcSEcCtD
Anagrelide—Infection—Docetaxel—lung cancer	0.000317	0.000358	CcSEcCtD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—lung cancer	0.000317	0.0028	CbGpPWpGaD
Anagrelide—Weight decreased—Doxorubicin—lung cancer	0.000317	0.000358	CcSEcCtD
Anagrelide—Feeling abnormal—Etoposide—lung cancer	0.000317	0.000357	CcSEcCtD
Anagrelide—Diarrhoea—Irinotecan—lung cancer	0.000316	0.000357	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—GNG11—lung cancer	0.000315	0.00278	CbGpPWpGaD
Anagrelide—Pneumonia—Doxorubicin—lung cancer	0.000314	0.000355	CcSEcCtD
Anagrelide—Gastrointestinal pain—Etoposide—lung cancer	0.000314	0.000355	CcSEcCtD
Anagrelide—Shock—Docetaxel—lung cancer	0.000314	0.000354	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTA4—lung cancer	0.000314	0.00277	CbGpPWpGaD
Anagrelide—Nervous system disorder—Docetaxel—lung cancer	0.000313	0.000353	CcSEcCtD
Anagrelide—Thrombocytopenia—Docetaxel—lung cancer	0.000313	0.000353	CcSEcCtD
Anagrelide—Visual impairment—Methotrexate—lung cancer	0.000312	0.000352	CcSEcCtD
Anagrelide—Tachycardia—Docetaxel—lung cancer	0.000312	0.000352	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—ADCY1—lung cancer	0.000311	0.00275	CbGpPWpGaD
Anagrelide—Feeling abnormal—Paclitaxel—lung cancer	0.000311	0.00035	CcSEcCtD
Anagrelide—Skin disorder—Docetaxel—lung cancer	0.00031	0.00035	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—GSTA2—lung cancer	0.00031	0.00273	CbGpPWpGaD
Anagrelide—Gastrointestinal pain—Paclitaxel—lung cancer	0.000308	0.000348	CcSEcCtD
Anagrelide—Diarrhoea—Gemcitabine—lung cancer	0.000308	0.000347	CcSEcCtD
Anagrelide—Renal failure—Doxorubicin—lung cancer	0.000307	0.000347	CcSEcCtD
Anagrelide—Dizziness—Irinotecan—lung cancer	0.000306	0.000345	CcSEcCtD
Anagrelide—Urticaria—Etoposide—lung cancer	0.000305	0.000344	CcSEcCtD
Anagrelide—Anorexia—Docetaxel—lung cancer	0.000305	0.000343	CcSEcCtD
Anagrelide—Body temperature increased—Etoposide—lung cancer	0.000304	0.000343	CcSEcCtD
Anagrelide—Abdominal pain—Etoposide—lung cancer	0.000304	0.000343	CcSEcCtD
Anagrelide—Urinary tract infection—Doxorubicin—lung cancer	0.000304	0.000343	CcSEcCtD
Anagrelide—Conjunctivitis—Doxorubicin—lung cancer	0.000304	0.000343	CcSEcCtD
Anagrelide—Eye disorder—Methotrexate—lung cancer	0.000303	0.000342	CcSEcCtD
Anagrelide—Tinnitus—Methotrexate—lung cancer	0.000302	0.000341	CcSEcCtD
Anagrelide—Asthenia—Cisplatin—lung cancer	0.000301	0.00034	CcSEcCtD
Anagrelide—Cardiac disorder—Methotrexate—lung cancer	0.000301	0.000339	CcSEcCtD
Anagrelide—Sweating—Doxorubicin—lung cancer	0.0003	0.000338	CcSEcCtD
Anagrelide—Urticaria—Paclitaxel—lung cancer	0.000299	0.000338	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—GSTA1—lung cancer	0.000299	0.00264	CbGpPWpGaD
Anagrelide—Hypotension—Docetaxel—lung cancer	0.000299	0.000337	CcSEcCtD
Anagrelide—Haematuria—Doxorubicin—lung cancer	0.000298	0.000336	CcSEcCtD
Anagrelide—Abdominal pain—Paclitaxel—lung cancer	0.000298	0.000336	CcSEcCtD
Anagrelide—Body temperature increased—Paclitaxel—lung cancer	0.000298	0.000336	CcSEcCtD
Anagrelide—Hepatobiliary disease—Doxorubicin—lung cancer	0.000296	0.000333	CcSEcCtD
Anagrelide—Epistaxis—Doxorubicin—lung cancer	0.000295	0.000333	CcSEcCtD
Anagrelide—Vomiting—Irinotecan—lung cancer	0.000294	0.000331	CcSEcCtD
Anagrelide—Sinusitis—Doxorubicin—lung cancer	0.000293	0.000331	CcSEcCtD
Anagrelide—Mediastinal disorder—Methotrexate—lung cancer	0.000292	0.000329	CcSEcCtD
Anagrelide—Rash—Irinotecan—lung cancer	0.000291	0.000329	CcSEcCtD
Anagrelide—Dermatitis—Irinotecan—lung cancer	0.000291	0.000328	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000291	0.000328	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—COL4A2—lung cancer	0.000291	0.00257	CbGpPWpGaD
Anagrelide—Chills—Methotrexate—lung cancer	0.000291	0.000328	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—PTHLH—lung cancer	0.00029	0.00256	CbGpPWpGaD
Anagrelide—Headache—Irinotecan—lung cancer	0.00029	0.000327	CcSEcCtD
Anagrelide—Insomnia—Docetaxel—lung cancer	0.000289	0.000326	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—lung cancer	0.000288	0.00254	CbGpPWpGaD
Anagrelide—Diarrhoea—Cisplatin—lung cancer	0.000287	0.000324	CcSEcCtD
Anagrelide—Paraesthesia—Docetaxel—lung cancer	0.000287	0.000324	CcSEcCtD
Anagrelide—Alopecia—Methotrexate—lung cancer	0.000286	0.000323	CcSEcCtD
Anagrelide—Vomiting—Gemcitabine—lung cancer	0.000286	0.000323	CcSEcCtD
Anagrelide—Dyspnoea—Docetaxel—lung cancer	0.000285	0.000321	CcSEcCtD
Anagrelide—Somnolence—Docetaxel—lung cancer	0.000284	0.00032	CcSEcCtD
Anagrelide—Rash—Gemcitabine—lung cancer	0.000284	0.00032	CcSEcCtD
Anagrelide—Dermatitis—Gemcitabine—lung cancer	0.000284	0.00032	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—GIPR—lung cancer	0.000283	0.0025	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ADCY1—lung cancer	0.000283	0.0025	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—AKR1C1—lung cancer	0.000282	0.00249	CbGpPWpGaD
Anagrelide—Malnutrition—Methotrexate—lung cancer	0.000282	0.000318	CcSEcCtD
Anagrelide—Haemoglobin—Doxorubicin—lung cancer	0.000282	0.000318	CcSEcCtD
Anagrelide—Headache—Gemcitabine—lung cancer	0.000282	0.000318	CcSEcCtD
Anagrelide—Rhinitis—Doxorubicin—lung cancer	0.000281	0.000317	CcSEcCtD
Anagrelide—Dyspepsia—Docetaxel—lung cancer	0.000281	0.000317	CcSEcCtD
Anagrelide—Hepatitis—Doxorubicin—lung cancer	0.000281	0.000316	CcSEcCtD
Anagrelide—Haemorrhage—Doxorubicin—lung cancer	0.000281	0.000316	CcSEcCtD
Anagrelide—Hypoaesthesia—Doxorubicin—lung cancer	0.000279	0.000315	CcSEcCtD
Anagrelide—Pharyngitis—Doxorubicin—lung cancer	0.000279	0.000314	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—UGT1A1—lung cancer	0.000278	0.00245	CbGpPWpGaD
Anagrelide—Decreased appetite—Docetaxel—lung cancer	0.000278	0.000313	CcSEcCtD
Anagrelide—Urinary tract disorder—Doxorubicin—lung cancer	0.000277	0.000313	CcSEcCtD
Anagrelide—Oedema peripheral—Doxorubicin—lung cancer	0.000276	0.000312	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Docetaxel—lung cancer	0.000276	0.000311	CcSEcCtD
Anagrelide—Asthenia—Etoposide—lung cancer	0.000276	0.000311	CcSEcCtD
Anagrelide—Connective tissue disorder—Doxorubicin—lung cancer	0.000276	0.000311	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—PPP2R1B—lung cancer	0.000276	0.00243	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—MAP2K1—lung cancer	0.000276	0.00243	CbGpPWpGaD
Anagrelide—Fatigue—Docetaxel—lung cancer	0.000275	0.000311	CcSEcCtD
Anagrelide—Urethral disorder—Doxorubicin—lung cancer	0.000275	0.00031	CcSEcCtD
Anagrelide—Nausea—Irinotecan—lung cancer	0.000274	0.00031	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—UGT1A1—lung cancer	0.000274	0.00242	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—COL4A3BP—lung cancer	0.000273	0.00241	CbGpPWpGaD
Anagrelide—Constipation—Docetaxel—lung cancer	0.000273	0.000308	CcSEcCtD
Anagrelide—Pain—Docetaxel—lung cancer	0.000273	0.000308	CcSEcCtD
Anagrelide—Back pain—Methotrexate—lung cancer	0.000273	0.000308	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—ANXA1—lung cancer	0.000272	0.0024	CbGpPWpGaD
Anagrelide—Pruritus—Etoposide—lung cancer	0.000272	0.000307	CcSEcCtD
Anagrelide—CYP1A2—Phase II conjugation—GSTP1—lung cancer	0.000272	0.0024	CbGpPWpGaD
Anagrelide—Visual impairment—Doxorubicin—lung cancer	0.00027	0.000305	CcSEcCtD
Anagrelide—Asthenia—Paclitaxel—lung cancer	0.00027	0.000305	CcSEcCtD
Anagrelide—Nausea—Gemcitabine—lung cancer	0.000267	0.000302	CcSEcCtD
Anagrelide—Vomiting—Cisplatin—lung cancer	0.000267	0.000301	CcSEcCtD
Anagrelide—Pruritus—Paclitaxel—lung cancer	0.000267	0.000301	CcSEcCtD
Anagrelide—Vision blurred—Methotrexate—lung cancer	0.000266	0.0003	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—SDC4—lung cancer	0.000265	0.00234	CbGpPWpGaD
Anagrelide—Rash—Cisplatin—lung cancer	0.000265	0.000298	CcSEcCtD
Anagrelide—Dermatitis—Cisplatin—lung cancer	0.000264	0.000298	CcSEcCtD
Anagrelide—Feeling abnormal—Docetaxel—lung cancer	0.000263	0.000297	CcSEcCtD
Anagrelide—Diarrhoea—Etoposide—lung cancer	0.000263	0.000297	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—PTHLH—lung cancer	0.000263	0.00232	CbGpPWpGaD
Anagrelide—Eye disorder—Doxorubicin—lung cancer	0.000262	0.000296	CcSEcCtD
Anagrelide—Ill-defined disorder—Methotrexate—lung cancer	0.000262	0.000295	CcSEcCtD
Anagrelide—Tinnitus—Doxorubicin—lung cancer	0.000262	0.000295	CcSEcCtD
Anagrelide—Gastrointestinal pain—Docetaxel—lung cancer	0.000261	0.000295	CcSEcCtD
Anagrelide—Anaemia—Methotrexate—lung cancer	0.000261	0.000294	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	0.000261	0.0023	CbGpPWpGaD
Anagrelide—Cardiac disorder—Doxorubicin—lung cancer	0.00026	0.000294	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—DUSP3—lung cancer	0.000259	0.00229	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—APP—lung cancer	0.000258	0.00228	CbGpPWpGaD
Anagrelide—Diarrhoea—Paclitaxel—lung cancer	0.000258	0.000291	CcSEcCtD
Anagrelide—Malaise—Methotrexate—lung cancer	0.000254	0.000287	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—RHEB—lung cancer	0.000254	0.00224	CbGpPWpGaD
Anagrelide—Dizziness—Etoposide—lung cancer	0.000254	0.000287	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—MMP1—lung cancer	0.000254	0.00224	CbGpPWpGaD
Anagrelide—Mediastinal disorder—Doxorubicin—lung cancer	0.000253	0.000285	CcSEcCtD
Anagrelide—Abdominal pain—Docetaxel—lung cancer	0.000253	0.000285	CcSEcCtD
Anagrelide—Body temperature increased—Docetaxel—lung cancer	0.000253	0.000285	CcSEcCtD
Anagrelide—Chills—Doxorubicin—lung cancer	0.000252	0.000284	CcSEcCtD
Anagrelide—Arrhythmia—Doxorubicin—lung cancer	0.000251	0.000283	CcSEcCtD
Anagrelide—CYP1A2—Phase II conjugation—GSTM1—lung cancer	0.00025	0.0022	CbGpPWpGaD
Anagrelide—Dizziness—Paclitaxel—lung cancer	0.000249	0.000281	CcSEcCtD
Anagrelide—Nausea—Cisplatin—lung cancer	0.000249	0.000281	CcSEcCtD
Anagrelide—Alopecia—Doxorubicin—lung cancer	0.000248	0.00028	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—ANXA1—lung cancer	0.000247	0.00218	CbGpPWpGaD
Anagrelide—Cough—Methotrexate—lung cancer	0.000246	0.000278	CcSEcCtD
Anagrelide—CYP1A2—Tryptophan metabolism—MDM2—lung cancer	0.000245	0.00216	CbGpPWpGaD
Anagrelide—Convulsion—Methotrexate—lung cancer	0.000244	0.000276	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—lung cancer	0.000244	0.00216	CbGpPWpGaD
Anagrelide—Vomiting—Etoposide—lung cancer	0.000244	0.000276	CcSEcCtD
Anagrelide—Malnutrition—Doxorubicin—lung cancer	0.000244	0.000276	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—APOA1—lung cancer	0.000243	0.00214	CbGpPWpGaD
Anagrelide—Rash—Etoposide—lung cancer	0.000242	0.000273	CcSEcCtD
Anagrelide—Dermatitis—Etoposide—lung cancer	0.000242	0.000273	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—GRM8—lung cancer	0.000241	0.00213	CbGpPWpGaD
Anagrelide—Headache—Etoposide—lung cancer	0.000241	0.000272	CcSEcCtD
Anagrelide—Flatulence—Doxorubicin—lung cancer	0.000241	0.000271	CcSEcCtD
Anagrelide—Chest pain—Methotrexate—lung cancer	0.00024	0.000271	CcSEcCtD
Anagrelide—Myalgia—Methotrexate—lung cancer	0.00024	0.000271	CcSEcCtD
Anagrelide—Arthralgia—Methotrexate—lung cancer	0.00024	0.000271	CcSEcCtD
Anagrelide—Tension—Doxorubicin—lung cancer	0.00024	0.00027	CcSEcCtD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	0.00024	0.00211	CbGpPWpGaD
Anagrelide—Vomiting—Paclitaxel—lung cancer	0.00024	0.00027	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000239	0.000269	CcSEcCtD
Anagrelide—Rash—Paclitaxel—lung cancer	0.000238	0.000268	CcSEcCtD
Anagrelide—Dermatitis—Paclitaxel—lung cancer	0.000237	0.000268	CcSEcCtD
Anagrelide—Discomfort—Methotrexate—lung cancer	0.000237	0.000268	CcSEcCtD
Anagrelide—Nervousness—Doxorubicin—lung cancer	0.000237	0.000268	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—lung cancer	0.000236	0.00209	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—HPGDS—lung cancer	0.000236	0.00209	CbGpPWpGaD
Anagrelide—Back pain—Doxorubicin—lung cancer	0.000236	0.000266	CcSEcCtD
Anagrelide—Headache—Paclitaxel—lung cancer	0.000236	0.000266	CcSEcCtD
Anagrelide—Muscle spasms—Doxorubicin—lung cancer	0.000235	0.000265	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—APP—lung cancer	0.000234	0.00207	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SKI—lung cancer	0.000233	0.00206	CbGpPWpGaD
Anagrelide—Confusional state—Methotrexate—lung cancer	0.000232	0.000262	CcSEcCtD
Anagrelide—Vision blurred—Doxorubicin—lung cancer	0.00023	0.00026	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—GSTT1—lung cancer	0.000229	0.00202	CbGpPWpGaD
Anagrelide—Asthenia—Docetaxel—lung cancer	0.000229	0.000258	CcSEcCtD
Anagrelide—Infection—Methotrexate—lung cancer	0.000229	0.000258	CcSEcCtD
Anagrelide—Nausea—Etoposide—lung cancer	0.000228	0.000258	CcSEcCtD
Anagrelide—Ill-defined disorder—Doxorubicin—lung cancer	0.000227	0.000256	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—CYP2A6—lung cancer	0.000227	0.002	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GCLC—lung cancer	0.000227	0.002	CbGpPWpGaD
Anagrelide—Pruritus—Docetaxel—lung cancer	0.000226	0.000255	CcSEcCtD
Anagrelide—Nervous system disorder—Methotrexate—lung cancer	0.000226	0.000255	CcSEcCtD
Anagrelide—Anaemia—Doxorubicin—lung cancer	0.000226	0.000255	CcSEcCtD
Anagrelide—Thrombocytopenia—Methotrexate—lung cancer	0.000225	0.000254	CcSEcCtD
Anagrelide—Nausea—Paclitaxel—lung cancer	0.000224	0.000252	CcSEcCtD
Anagrelide—Skin disorder—Methotrexate—lung cancer	0.000224	0.000252	CcSEcCtD
Anagrelide—Hyperhidrosis—Methotrexate—lung cancer	0.000223	0.000251	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—PIK3CG—lung cancer	0.000222	0.00196	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS2—lung cancer	0.000221	0.00195	CbGpPWpGaD
Anagrelide—Malaise—Doxorubicin—lung cancer	0.00022	0.000248	CcSEcCtD
Anagrelide—Anorexia—Methotrexate—lung cancer	0.000219	0.000248	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—EGF—lung cancer	0.000219	0.00193	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—lung cancer	0.000219	0.00193	CbGpPWpGaD
Anagrelide—Syncope—Doxorubicin—lung cancer	0.000219	0.000247	CcSEcCtD
Anagrelide—Diarrhoea—Docetaxel—lung cancer	0.000219	0.000247	CcSEcCtD
Anagrelide—Palpitations—Doxorubicin—lung cancer	0.000216	0.000243	CcSEcCtD
Anagrelide—Hypotension—Methotrexate—lung cancer	0.000215	0.000243	CcSEcCtD
Anagrelide—Loss of consciousness—Doxorubicin—lung cancer	0.000215	0.000242	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—lung cancer	0.000213	0.00188	CbGpPWpGaD
Anagrelide—Cough—Doxorubicin—lung cancer	0.000213	0.00024	CcSEcCtD
Anagrelide—Convulsion—Doxorubicin—lung cancer	0.000212	0.000239	CcSEcCtD
Anagrelide—Dizziness—Docetaxel—lung cancer	0.000211	0.000238	CcSEcCtD
Anagrelide—Hypertension—Doxorubicin—lung cancer	0.000211	0.000238	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Methotrexate—lung cancer	0.00021	0.000237	CcSEcCtD
Anagrelide—Insomnia—Methotrexate—lung cancer	0.000208	0.000235	CcSEcCtD
Anagrelide—Chest pain—Doxorubicin—lung cancer	0.000208	0.000235	CcSEcCtD
Anagrelide—Arthralgia—Doxorubicin—lung cancer	0.000208	0.000235	CcSEcCtD
Anagrelide—Myalgia—Doxorubicin—lung cancer	0.000208	0.000235	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PLBD1—lung cancer	0.000207	0.00183	CbGpPWpGaD
Anagrelide—Paraesthesia—Methotrexate—lung cancer	0.000207	0.000233	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—lung cancer	0.000207	0.00182	CbGpPWpGaD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000207	0.000233	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—CREBBP—lung cancer	0.000206	0.00181	CbGpPWpGaD
Anagrelide—Discomfort—Doxorubicin—lung cancer	0.000205	0.000232	CcSEcCtD
Anagrelide—Dyspnoea—Methotrexate—lung cancer	0.000205	0.000232	CcSEcCtD
Anagrelide—Somnolence—Methotrexate—lung cancer	0.000205	0.000231	CcSEcCtD
Anagrelide—Dry mouth—Doxorubicin—lung cancer	0.000203	0.000229	CcSEcCtD
Anagrelide—Vomiting—Docetaxel—lung cancer	0.000203	0.000229	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PXN—lung cancer	0.000203	0.00179	CbGpPWpGaD
Anagrelide—Dyspepsia—Methotrexate—lung cancer	0.000203	0.000229	CcSEcCtD
Anagrelide—Rash—Docetaxel—lung cancer	0.000201	0.000227	CcSEcCtD
Anagrelide—Dermatitis—Docetaxel—lung cancer	0.000201	0.000227	CcSEcCtD
Anagrelide—Confusional state—Doxorubicin—lung cancer	0.000201	0.000227	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—AVP—lung cancer	0.000201	0.00177	CbGpPWpGaD
Anagrelide—Decreased appetite—Methotrexate—lung cancer	0.0002	0.000226	CcSEcCtD
Anagrelide—Headache—Docetaxel—lung cancer	0.0002	0.000226	CcSEcCtD
Anagrelide—Oedema—Doxorubicin—lung cancer	0.000199	0.000225	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Methotrexate—lung cancer	0.000199	0.000224	CcSEcCtD
Anagrelide—Fatigue—Methotrexate—lung cancer	0.000199	0.000224	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—GRP—lung cancer	0.000199	0.00175	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—OXTR—lung cancer	0.000199	0.00175	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKR1C1—lung cancer	0.000199	0.00175	CbGpPWpGaD
Anagrelide—Infection—Doxorubicin—lung cancer	0.000198	0.000223	CcSEcCtD
Anagrelide—Pain—Methotrexate—lung cancer	0.000197	0.000222	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—lung cancer	0.000197	0.00174	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—lung cancer	0.000197	0.00174	CbGpPWpGaD
Anagrelide—Shock—Doxorubicin—lung cancer	0.000196	0.000221	CcSEcCtD
Anagrelide—Nervous system disorder—Doxorubicin—lung cancer	0.000196	0.000221	CcSEcCtD
Anagrelide—Thrombocytopenia—Doxorubicin—lung cancer	0.000195	0.00022	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—PIK3CD—lung cancer	0.000195	0.00172	CbGpPWpGaD
Anagrelide—Tachycardia—Doxorubicin—lung cancer	0.000195	0.000219	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—lung cancer	0.000194	0.00171	CbGpPWpGaD
Anagrelide—Skin disorder—Doxorubicin—lung cancer	0.000194	0.000218	CcSEcCtD
Anagrelide—Hyperhidrosis—Doxorubicin—lung cancer	0.000193	0.000217	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—CYP2E1—lung cancer	0.000193	0.0017	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ALB—lung cancer	0.000192	0.0017	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—lung cancer	0.000191	0.00169	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—lung cancer	0.000191	0.00169	CbGpPWpGaD
Anagrelide—Anorexia—Doxorubicin—lung cancer	0.00019	0.000214	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP2E1—lung cancer	0.00019	0.00168	CbGpPWpGaD
Anagrelide—Nausea—Docetaxel—lung cancer	0.00019	0.000214	CcSEcCtD
Anagrelide—Feeling abnormal—Methotrexate—lung cancer	0.00019	0.000214	CcSEcCtD
Anagrelide—Gastrointestinal pain—Methotrexate—lung cancer	0.000188	0.000212	CcSEcCtD
Anagrelide—Hypotension—Doxorubicin—lung cancer	0.000186	0.00021	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—lung cancer	0.000186	0.00164	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GNG11—lung cancer	0.000186	0.00164	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—lung cancer	0.000184	0.00162	CbGpPWpGaD
Anagrelide—Urticaria—Methotrexate—lung cancer	0.000183	0.000206	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—AVP—lung cancer	0.000182	0.00161	CbGpPWpGaD
Anagrelide—Body temperature increased—Methotrexate—lung cancer	0.000182	0.000205	CcSEcCtD
Anagrelide—Abdominal pain—Methotrexate—lung cancer	0.000182	0.000205	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000182	0.000205	CcSEcCtD
Anagrelide—Insomnia—Doxorubicin—lung cancer	0.00018	0.000203	CcSEcCtD
Anagrelide—Paraesthesia—Doxorubicin—lung cancer	0.000179	0.000202	CcSEcCtD
Anagrelide—Dyspnoea—Doxorubicin—lung cancer	0.000178	0.0002	CcSEcCtD
Anagrelide—Somnolence—Doxorubicin—lung cancer	0.000177	0.0002	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—VEGFC—lung cancer	0.000177	0.00156	CbGpPWpGaD
Anagrelide—Dyspepsia—Doxorubicin—lung cancer	0.000175	0.000198	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—RAF1—lung cancer	0.000174	0.00154	CbGpPWpGaD
Anagrelide—Decreased appetite—Doxorubicin—lung cancer	0.000173	0.000195	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000172	0.000194	CcSEcCtD
Anagrelide—Fatigue—Doxorubicin—lung cancer	0.000172	0.000194	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—lung cancer	0.000171	0.00151	CbGpPWpGaD
Anagrelide—Pain—Doxorubicin—lung cancer	0.00017	0.000192	CcSEcCtD
Anagrelide—Constipation—Doxorubicin—lung cancer	0.00017	0.000192	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—PIK3CB—lung cancer	0.00017	0.0015	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—lung cancer	0.000168	0.00148	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—lung cancer	0.000168	0.00148	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADCY1—lung cancer	0.000167	0.00147	CbGpPWpGaD
Anagrelide—Asthenia—Methotrexate—lung cancer	0.000165	0.000186	CcSEcCtD
Anagrelide—Feeling abnormal—Doxorubicin—lung cancer	0.000164	0.000185	CcSEcCtD
Anagrelide—Gastrointestinal pain—Doxorubicin—lung cancer	0.000163	0.000184	CcSEcCtD
Anagrelide—Pruritus—Methotrexate—lung cancer	0.000163	0.000184	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PPP2R1B—lung cancer	0.000163	0.00144	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SMARCA4—lung cancer	0.000163	0.00144	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—lung cancer	0.000161	0.00142	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTP1—lung cancer	0.000159	0.0014	CbGpPWpGaD
Anagrelide—Urticaria—Doxorubicin—lung cancer	0.000158	0.000179	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—lung cancer	0.000158	0.0014	CbGpPWpGaD
Anagrelide—Abdominal pain—Doxorubicin—lung cancer	0.000158	0.000178	CcSEcCtD
Anagrelide—Body temperature increased—Doxorubicin—lung cancer	0.000158	0.000178	CcSEcCtD
Anagrelide—Diarrhoea—Methotrexate—lung cancer	0.000158	0.000178	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—HSPB1—lung cancer	0.000157	0.00139	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTP1—lung cancer	0.000157	0.00138	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IL2—lung cancer	0.000156	0.00138	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTHLH—lung cancer	0.000155	0.00137	CbGpPWpGaD
Anagrelide—Dizziness—Methotrexate—lung cancer	0.000152	0.000172	CcSEcCtD
Anagrelide—Vomiting—Methotrexate—lung cancer	0.000146	0.000165	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ANXA1—lung cancer	0.000146	0.00129	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTM1—lung cancer	0.000146	0.00129	CbGpPWpGaD
Anagrelide—Rash—Methotrexate—lung cancer	0.000145	0.000164	CcSEcCtD
Anagrelide—Dermatitis—Methotrexate—lung cancer	0.000145	0.000164	CcSEcCtD
Anagrelide—Headache—Methotrexate—lung cancer	0.000144	0.000163	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTM1—lung cancer	0.000144	0.00127	CbGpPWpGaD
Anagrelide—Asthenia—Doxorubicin—lung cancer	0.000143	0.000161	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—FLT1—lung cancer	0.000141	0.00125	CbGpPWpGaD
Anagrelide—Pruritus—Doxorubicin—lung cancer	0.000141	0.000159	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CG—lung cancer	0.00014	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—EP300—lung cancer	0.00014	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APP—lung cancer	0.000138	0.00122	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOTCH3—lung cancer	0.000138	0.00122	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP1A1—lung cancer	0.000138	0.00122	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF9—lung cancer	0.000137	0.00121	CbGpPWpGaD
Anagrelide—Nausea—Methotrexate—lung cancer	0.000137	0.000154	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP1A1—lung cancer	0.000137	0.0012	CbGpPWpGaD
Anagrelide—Diarrhoea—Doxorubicin—lung cancer	0.000136	0.000154	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—SRC—lung cancer	0.000136	0.0012	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—lung cancer	0.000135	0.00119	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—POMC—lung cancer	0.000133	0.00118	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VEGFA—lung cancer	0.000133	0.00117	CbGpPWpGaD
Anagrelide—Dizziness—Doxorubicin—lung cancer	0.000132	0.000149	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—JUNB—lung cancer	0.000131	0.00116	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NRAS—lung cancer	0.000131	0.00116	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CG—lung cancer	0.000127	0.00112	CbGpPWpGaD
Anagrelide—Vomiting—Doxorubicin—lung cancer	0.000127	0.000143	CcSEcCtD
Anagrelide—Rash—Doxorubicin—lung cancer	0.000126	0.000142	CcSEcCtD
Anagrelide—Dermatitis—Doxorubicin—lung cancer	0.000126	0.000142	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—MAPK3—lung cancer	0.000125	0.00111	CbGpPWpGaD
Anagrelide—Headache—Doxorubicin—lung cancer	0.000125	0.000141	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CD—lung cancer	0.000123	0.00109	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—COL4A3BP—lung cancer	0.000122	0.00107	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AZIN2—lung cancer	0.000122	0.00107	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—POMC—lung cancer	0.000121	0.00107	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STK11—lung cancer	0.000119	0.00105	CbGpPWpGaD
Anagrelide—Nausea—Doxorubicin—lung cancer	0.000118	0.000134	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—IL6R—lung cancer	0.000118	0.00104	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FOXO3—lung cancer	0.000115	0.00101	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	0.000114	0.001	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—KRAS—lung cancer	0.000113	0.000995	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAP2K1—lung cancer	0.000113	0.000994	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CD—lung cancer	0.000112	0.000987	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	0.00011	0.00097	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AVP—lung cancer	0.000108	0.00095	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CB—lung cancer	0.000107	0.000947	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1R—lung cancer	0.000104	0.000915	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CA—lung cancer	0.000104	0.000914	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ATP5H—lung cancer	0.000104	0.000914	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—POMC—lung cancer	0.000103	0.000911	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL8—lung cancer	0.000103	0.00091	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HES1—lung cancer	0.000102	0.000898	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TP53—lung cancer	0.0001	0.000884	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—RAF1—lung cancer	9.99e-05	0.000881	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—IL2—lung cancer	9.86e-05	0.00087	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CB—lung cancer	9.75e-05	0.00086	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—HRAS—lung cancer	9.58e-05	0.000846	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	9.51e-05	0.00084	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCL8—lung cancer	9.37e-05	0.000827	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ERBB3—lung cancer	9.31e-05	0.000821	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLBD1—lung cancer	9.23e-05	0.000814	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	9.08e-05	0.000801	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL2—lung cancer	8.95e-05	0.00079	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TERT—lung cancer	8.92e-05	0.000787	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGFR1—lung cancer	8.66e-05	0.000764	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HIF1A—lung cancer	8.53e-05	0.000753	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT1—lung cancer	8.46e-05	0.000747	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD17B10—lung cancer	8.44e-05	0.000745	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOA1—lung cancer	8.23e-05	0.000727	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KDR—lung cancer	8.16e-05	0.00072	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CKB—lung cancer	7.85e-05	0.000692	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APC—lung cancer	7.52e-05	0.000663	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KIT—lung cancer	7.52e-05	0.000663	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CG—lung cancer	7.52e-05	0.000663	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—NRAS—lung cancer	7.52e-05	0.000663	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EGF—lung cancer	7.43e-05	0.000656	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM2—lung cancer	7.38e-05	0.000651	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CNDP2—lung cancer	7.38e-05	0.000651	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAPK3—lung cancer	7.2e-05	0.000635	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTMR3—lung cancer	7.18e-05	0.000633	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—POMC—lung cancer	7.15e-05	0.000631	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—BRAF—lung cancer	7.07e-05	0.000623	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PGAM1—lung cancer	6.99e-05	0.000617	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6R—lung cancer	6.98e-05	0.000616	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CREBBP—lung cancer	6.97e-05	0.000615	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EGFR—lung cancer	6.85e-05	0.000604	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2A7—lung cancer	6.67e-05	0.000589	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAP2K1—lung cancer	6.65e-05	0.000587	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CD—lung cancer	6.61e-05	0.000583	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CA—lung cancer	6.55e-05	0.000578	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SDC4—lung cancer	6.53e-05	0.000576	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—KRAS—lung cancer	6.47e-05	0.000571	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—RRM1—lung cancer	5.95e-05	0.000525	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA3—lung cancer	5.95e-05	0.000525	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CA—lung cancer	5.94e-05	0.000524	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MDM2—lung cancer	5.92e-05	0.000522	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RAF1—lung cancer	5.9e-05	0.000521	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ERBB2—lung cancer	5.84e-05	0.000515	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MTOR—lung cancer	5.76e-05	0.000508	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CB—lung cancer	5.76e-05	0.000508	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—B4GALT5—lung cancer	5.59e-05	0.000493	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL8—lung cancer	5.53e-05	0.000488	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—HRAS—lung cancer	5.5e-05	0.000485	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA4—lung cancer	5.44e-05	0.00048	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT1—lung cancer	5.35e-05	0.000472	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	5.32e-05	0.000469	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA2—lung cancer	5.3e-05	0.000468	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASP3—lung cancer	5.3e-05	0.000467	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL2—lung cancer	5.29e-05	0.000467	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—lung cancer	5.26e-05	0.000464	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCND1—lung cancer	5.16e-05	0.000455	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—JUN—lung cancer	5.15e-05	0.000454	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA1—lung cancer	5.11e-05	0.000451	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCC3—lung cancer	5.06e-05	0.000446	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP9—lung cancer	5.01e-05	0.000442	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1A—lung cancer	4.99e-05	0.00044	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTEN—lung cancer	4.98e-05	0.000439	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKR1C1—lung cancer	4.9e-05	0.000432	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT1—lung cancer	4.86e-05	0.000428	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UGT1A1—lung cancer	4.75e-05	0.000419	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EP300—lung cancer	4.75e-05	0.000419	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SRC—lung cancer	4.62e-05	0.000407	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GNG11—lung cancer	4.58e-05	0.000405	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	4.56e-05	0.000402	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—lung cancer	4.5e-05	0.000397	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STAT3—lung cancer	4.45e-05	0.000393	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NRAS—lung cancer	4.44e-05	0.000392	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDOA—lung cancer	4.36e-05	0.000385	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK3—lung cancer	4.25e-05	0.000375	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NCOA3—lung cancer	4.24e-05	0.000374	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	4.16e-05	0.000367	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MYC—lung cancer	4.14e-05	0.000365	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADCY1—lung cancer	4.12e-05	0.000364	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCG2—lung cancer	4.12e-05	0.000364	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EGFR—lung cancer	4.05e-05	0.000357	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ENO2—lung cancer	4.04e-05	0.000357	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HPGDS—lung cancer	4.04e-05	0.000357	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPP2R1B—lung cancer	4.02e-05	0.000354	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	3.96e-05	0.00035	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTT1—lung cancer	3.92e-05	0.000346	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2A6—lung cancer	3.88e-05	0.000342	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GCLC—lung cancer	3.88e-05	0.000342	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	3.86e-05	0.000341	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KRAS—lung cancer	3.82e-05	0.000337	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ENO1—lung cancer	3.67e-05	0.000324	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	3.66e-05	0.000323	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	3.61e-05	0.000319	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CA—lung cancer	3.51e-05	0.00031	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TP53—lung cancer	3.4e-05	0.0003	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2E1—lung cancer	3.3e-05	0.000291	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NQO1—lung cancer	3.26e-05	0.000288	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HRAS—lung cancer	3.25e-05	0.000287	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.19e-05	0.000282	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.16e-05	0.000279	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—lung cancer	3.11e-05	0.000274	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—STK11—lung cancer	2.94e-05	0.000259	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT1—lung cancer	2.87e-05	0.000253	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.76e-05	0.000243	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTP1—lung cancer	2.72e-05	0.00024	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CAT—lung cancer	2.64e-05	0.000233	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.63e-05	0.000232	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCB1—lung cancer	2.57e-05	0.000227	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TYMS—lung cancer	2.53e-05	0.000223	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM1—lung cancer	2.5e-05	0.00022	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP1A1—lung cancer	2.37e-05	0.000209	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ERCC2—lung cancer	2.35e-05	0.000207	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOA1—lung cancer	2.03e-05	0.000179	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.94e-05	0.000172	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CG—lung cancer	1.85e-05	0.000164	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—POMC—lung cancer	1.77e-05	0.000156	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CREBBP—lung cancer	1.72e-05	0.000152	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CD—lung cancer	1.63e-05	0.000144	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALB—lung cancer	1.61e-05	0.000142	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CB—lung cancer	1.42e-05	0.000125	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—lung cancer	1.41e-05	0.000124	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTEN—lung cancer	1.23e-05	0.000108	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—EP300—lung cancer	1.17e-05	0.000103	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CA—lung cancer	8.66e-06	7.64e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKT1—lung cancer	7.08e-06	6.24e-05	CbGpPWpGaD
